Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.38 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196738 | 0.88 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1KDM1AMAOAMAOB | |
| SCHEMBL27781047 | 0.82 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BHDAC4 | |
| SCHEMBL4550247 | 0.80 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1SMN1; SMN2 | |
| SCHEMBL3104303 | 0.80 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BHDAC4 | |
| SCHEMBL8362221 | 0.78 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BHDAC4 | |
| SCHEMBL20842232 | 0.78 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BHDAC4 | |
| SCHEMBL3068209 | 0.78 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BHDAC4 | |
| SCHEMBL22878132 | 0.78 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BHDAC4 | |
| SCHEMBL3940873 | 0.78 | ACKR3 (0.43) | L3MBTL3L3MBTL1CDYLCDY1; CDY1BMEN1 | |
| SCHEMBL31387583 | 0.78 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1CDYLCDY1; CDY1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524411-A | — | — | 2011-09-01 | — | — | JP | claimed |
| CN-102124000-A | Pyridine compounds | ASTRAZENECA AB | 2011-07-13 | — | — | CN | claimed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | claimed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| CN-1077891-C | 5-phenyl-3- (piperidin-4-yl) -1,3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT4 or H3 receptor ligands | SYNTHELABO (FR) | 2002-01-16 | — | — | CN | claimed |
| US-5929089-A | ANTISEROTONINE AGENT | SYNTHELABO (FR) | 1999-07-27 | — | — | US | claimed |
| EP-0863897-B1 | 5-PHENYL-3-(PIPERIDIN-4-YL)-1,3,4-OXADIAZOL-2(3H)-ONE DERIVATIVES FOR USE AS 5-HT4- OR H3-RECEPTOR LIGANDS | SYNTHELABO (FR) | 1999-06-16 | — | — | EP | claimed |
| CN-1202169-A | 5-phenyl-3- (piperidin-4-yl) -1, 3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT 4 or H3 receptor ligands | SYNTHELABO (FR) | 1998-12-16 | — | — | CN | claimed |
| CN-102124000-B | Pyridine compounds | ASTRAZENECA AB | 2014-09-17 | — | — | CN | disclosed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-5929089-A | ANTISEROTONINE AGENT | SYNTHELABO (FR) | 1999-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | L3MBTL3 1385/4885L3MBTL1 1887/4885CDYL 1986/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | L3MBTL3 4396/4885L3MBTL1 4279/4885CDYL 1611/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | L3MBTL3 2698/4885L3MBTL1 3239/4885CDYL 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.